Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028160 | 0.79 | CYP3A4 (0.50) | CYP3A4CYP1A2CYP2D6ADORA2BKMT2A | |
| SCHEMBL6675403 | 0.75 | CYP3A4 (0.52) | CYP3A4CYP1A2CYP2D6ADORA2BKMT2A | |
| SCHEMBL3807230 | 0.73 | ALDH1A1 (0.41) | CYP3A4CYP1A2CYP2D6GAACASP3 | |
| SCHEMBL28968571 | 0.70 | CYP3A4 (0.48) | CYP3A4CYP1A2CYP2D6ADORA2BKMT2A | |
| SCHEMBL20417809 | 0.70 | SMN1; SMN2 (0.42) | CYP3A4CYP1A2CYP2D6SLC2A1KMT2A | |
| SCHEMBL29736630 | 0.70 | KMT2A (0.41) | CYP3A4CYP1A2CYP2D6KMT2ANPC1 | |
| SCHEMBL7256423 | 0.68 | P2RX4 (0.39) | KMT2ANPC1RAB9AGAAMEN1 | |
| SCHEMBL1381419 | 0.67 | POLB (0.46) | KMT2ANPC1RAB9AGAACASP3 | |
| SCHEMBL17563247 | 0.67 | NPC1 (0.40) | KMT2ANPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL1567297 | 0.66 | CRBN (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2294076-B1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED REPLICATION OF NUCLEIC ACID | TRILINK BIOTECHNOLOGIES (US) | 2017-03-08 | — | — | EP | claimed |
| EP-2294076-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TriLink BioTechnologies (US) | 2011-03-16 | — | — | EP | claimed |
| US-20100003724-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TriLink Bio Technologies | 2010-01-07 | — | — | US | claimed |
| WO-2009151921-A1 | CHEMICALLY MODIFIED NUCLEOSIDE 5'-TRIPHOSPHATES FOR THERMALLY INITIATED AMPLIFICATION OF NUCLEIC ACID | TRILINK BIOTECHNOLOGIES (US) | 2009-12-17 | — | — | WO | claimed |
| US-20090011488-A1 | METHODS FOR STORING COMPOSITIONS USEFUL FOR SYNTHESIZING NUCLEIC ACID MOLECULES | ROSETTA INPHARMATICS, LLC (US) | 2009-01-08 | — | — | US | claimed |
| US-20240335551-A1 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | OLIX US, INC. | 2024-10-10 | — | — | US | disclosed |
| EP-4341269-A1 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | Olix US, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2022246195-A1 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | OLIX US, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| US-20210301324-A1 | METHOD FOR ANALYZING FUNCTIONAL SUBUNIT PAIR GENE OF T CELL RECEPTOR AND B CELL RECEPTOR | REPERTOIRE GENESIS INCORPORATION (JP) | 2021-09-30 | — | — | US | disclosed |
| EP-3842550-A1 | METHOD FOR ANALYZING FUNCTIONAL SUBUNIT PAIR GENE OF T CELL RECEPTOR AND B CELL RECEPTOR | Repertoire Genesis Incorporation (JP) | 2021-06-30 | — | — | EP | disclosed |
| US-20190300934-A1 | T-CELL RECEPTOR AND B-CELL RECEPTOR REPERTOIRE ANALYSIS SYSTEM USING ONE-STEP REVERSE TRANSCRIPTION TEMPLATE-SWITCHING PCR | RIKEN (JP) | 2019-10-03 | — | — | US | disclosed |
| US-20190169679-A1 | ONE-STEP REVERSE TRANSCRIPTION TEMPLATE-SWITCHING PCR | RIKEN (JP) | 2019-06-06 | — | — | US | disclosed |
| EP-1339699-A1 | SUBSTITUTED AMIDOALKYL URACILS AND THE USE THEREOF | Bayer Aktiengesellschaft (DE) | 2003-09-03 | — | — | EP | disclosed |
| EP-1303497-A1 | SUBSTITUTED AMIDOALKYL-URACILS AS PARP INHIBITORS | Bayer Aktiengesellschaft (DE) | 2003-04-23 | — | — | EP | disclosed |
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | US | disclosed |
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | US | disclosed |
| WO-2002040455-A8 | SUBSTITUTED AMIDOALKYL URACILS AND THEIR USE AS INHIBITORS OF THE POLY(ADP-RIBOSE) SYNTHETASE (PARS) | BAYER AG (DE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002040455-A1 | SUBSTITUTED AMIDOALKYL URACILS AND THEIR USE AS INHIBITORS OF THE POLY(ADP-RIBOSE) SYNTHETASE (PARS) | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002006247-A8 | SUBSTITUTED AMIDOALKYL-URACILS AS PARP INHIBITORS | BAYER AG (DE) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002006247-A1 | SUBSTITUTED AMIDOALKYL-URACILS AS PARP INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335551-A1 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | FGB, SELP, PTMS | CYP3A4 2842/4885CYP1A2 3659/4885CYP2D6 2428/4885 |
| US-20030022905-A1 | Substituted amidoalkyl-uracils and their use | UNG, UMPS, TYMP | CYP3A4 682/4885CYP1A2 275/4885CYP2D6 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.